Aclaris Therapeutics (ACRS) Reports In-Line Q4 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
March 18, 2019 7:01 AM EDTProduct Sales of $3.9 Million for Fiscal Year 2018Initiates Financial Guidance for Full Year 2019Management to Host Conference Call at 8:00 AM ET today
WAYNE, Pa., March 18, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced financial results for the fourth quarter and full year 2018, and provided an update on its clinical development and commercial programs.  Â
In November 2018, Aclaris acquired the worldwide rights to RHOFADE® (oxymetazoline hydrochloride) cream, 1% from... More